1. Statins and Glucose Metabolism: Are All Agents Alike?

2. Goals

3. JUPITER Increased Incidence of T2D With Rosuvastatin

4. Statins and New-Onset T2D: Meta-Analysis of 13 Clinical Trials

5. T2D Risk: No Difference Between Most Statins

6. Statins and New-Onset T2D: Meta-Analysis of 13 Clinical Trials

7. WOSCOPS and LIPID Trials

8. WOSCOPS

9. WOSCOPS Reduction in LDL-C

10. Statins and the Development of Diabetes

11. Questions Remain

12. Pitavastatin Does Not Adversely Affect FBG, HbA1c, or T2D Development

13. Pitavastatin Treatment for Increased ASCVD Risk in HIV Infection

14. J-PREDICT Primary Outcome: Cumulative Incidence of Diabetes

15. Risk for New-Onset T2D Stratified by Risk Factors and Statin Dose

16. Risk Factors

17. Risk for New-Onset T2D Stratified by Age

18. Trajectories to Developing T2D

19. Key Factors for Reduction of CV Events

20. JUPITER: CV Benefit vs T2D Risk

21. CV/T2D Risk

22. T2D and Macrovascular Disease

23. Pitavastatin Has Neutral Effect on FBG Across the Dose Range

24. Pitavastatin and Pravastatin: Minimal CYP Involvement

25. CYP Systems

26. How Statins Impair Glucose and Insulin Metabolism

27. LDL-Rs and Genetic Targets

28. Not Just the HMG-CoA Reductase

29. Conclusions: Statin-Associated T2D

30. Multidisciplinary Team Approach: Preventing CVD and T2D

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)